Customised Services in Preclinical Inflammation

Scientific Reports

We value connection with academia and actively engage in research programmes, including exchange of personel with academic institutions, to keep up to date with the current findings and methodology and continuous development of services. We are expanding our portfolio with new models as well as refining the models we are already providing, with the aim of being a reliable and cost efficient provider of preclinical models of autoimmunity and inflammation.

We have a strong academic background in animal models of inflammation and autoimmunity. Redoxis was originally founded as a R&D company with focus on development of small molecules regulating oxidation status of cells for treatment of autoimmune conditions. That project is since May 2016 continued in our subsidiary ProNoxis.

Publication list: